Levodopa And Pramipexole Combination Therapy Efficacy In Vietnamese Patients With Parkinson’s Disease: A Randomized Controlled Trial

Author:

Le Minh Van1,Diep Dat Tien1,Tran Tam Thai Thanh1,Pham Tho Kieu Anh1,Tran Bao Lam Thai1ORCID,Nguyen Thang1ORCID

Affiliation:

1. Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam

Abstract

Early diagnosis and appropriate treatment of Parkinson's disease to minimize the adverse effects of the disease and drug side effects on the patient. Using levodopa combined with pramipexole is an effective therapy for treating Parkinson's disease. Objectives — This study aims to evaluate the treatment outcome of combination therapy with levodopa and pramipexole compared to levodopa monotherapy in Vietnamese Parkinson's patients. Material and Methods — A randomized controlled clinical trial with a 1:1 randomized ratio of 80 individuals with Parkinson's disease. The intervention group received a combination therapy with levodopa/benserazide and pramipexole, and the control group received a monotherapy with levodopa/benserazide. Motor symptoms, non-motor symptoms, The Unified Parkinson's Disease Rating (UPDRS), and The Parkinson's Disease Questionnaire (PDQ-39) scores were assessed before, after, and a follow-up period of 1 and 4 weeks after discharge to evaluate the treatment outcome. Results — Combining therapy with levodopa and pramipexole led to statistically significant improvements in UPDRS and PDQ-39 scores (p<0.05). The mean difference in UPDRS parts I, II, and III after 4 weeks of discharge was -0.5 (p=0.014), -1.68 (p=0.005), and -2.52 (p=0.010) respectively. The quality of life was also enhanced by combining therapy due to a better reduction of PDQ-39 score: 26.0±6.3 versus 32.7±6.4 (p<0.001). The most common side effects were headache, nausea/vomiting, and somnolence. Conclusions — Treatment with levodopa combined with pramipexole improves clinical symptoms and quality of life in patients with Parkinson's, as evidenced by improvements in UPDRS and PDQ-39 scores.

Publisher

LLC Science and Innovations

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3